Skip to content
Menu

Morgan Stanley Maintains Overweight on Generate Biomedicines, Lowers Price Target to $21

Benzinga Newsdesk 12 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and lowers the price target from $22 to $21.

Morgan Stanley analyst Sean Laaman maintains Generate Biomedicines (NASDAQ:GENB) with a Overweight and lowers the price target from $22 to $21.

Read at benzinga.com